CLINICAL_TRIALS ClinicalTrials.gov record update

Phase Ib/II Study of Grapiprant (IK-007) and Eribulin Combination Treatment for Metastatic Inflammatory Breast Cancer (mIBC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05041101
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:41.615611+00:00
Published At: 2025-06-13T00:00:00+00:00
Record Updated At: 2025-06-13
Results Posted At: 2025-06-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Breast Inflammatory Carcinoma", "Recurrent Breast Inflammatory Carcinoma", "Stage IV Breast Inflammatory Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-13"
protocolSection.identificationModule.nctId: "NCT05041101"
protocolSection.identificationModule.officialTitle: "Phase Ib/II Study of Grapiprant (IK-007) and Eribulin Combination Treatment for Metastatic Inflammatory Breast Cancer (mIBC)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-06-13"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.